Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020;5(1):e000614.
doi: 10.1136/esmoopen-2019-000614. Epub 2020 Sep 30.

MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis

Wenfeng Fang  1 , Huaqiang Zhou  2 , Jiayi Shen  3 , Jianwen Li  4 , Yaxiong Zhang  2 , Shaodong Hong  2 , Li Zhang  5
Affiliations

MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis

Wenfeng Fang et al. ESMO Open. 2020.
No abstract available

Keywords: MDM2/4; biomarker; immune checkpoint inhibitors; pan-cancer.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Overall survival (OS) of patients with MDM2/4 AMP versus those without MDM2/4 amplification (ICI cohort (A) and non-ICI cohort (C)). MDM2/4 AMP (with TMB-H or TMB-L) suggested the shortest OS as compared with higher levels of MSI and non-MDM2/4 AMP (with TMB-H or TMB-L) (B). (D) Prevalence of MDM2/4 amplification in 30 118 patients with different cancer types. AMP, amplification; ICI, immune checkpoint inhibitors; MSI, microsatellite instability; TMB, tumour mutational burden.
See this image and copyright information in PMC

References

    1. Topalian SL, Hodi FS, Brahmer JR, et al. . Five-Year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or Non–Small cell lung cancer treated with nivolumab. JAMA Oncol 2019;5:1411–20. 10.1001/jamaoncol.2019.2187 - DOI - PMC - PubMed
    1. Topalian SL, Hodi FS, Brahmer JR, et al. . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54. 10.1056/NEJMoa1200690 - DOI - PMC - PubMed
    1. Champiat S, Dercle L, Ammari S, et al. . Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017;23:1920–8. 10.1158/1078-0432.CCR-16-1741 - DOI - PubMed
    1. Rizvi H, Sanchez-Vega F, La K, et al. . Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol 2018;36:633–41. 10.1200/JCO.2017.75.3384 - DOI - PMC - PubMed
    1. Singavi AK, Menon S, Kilari D, et al. . 1140PDPredictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) – analysis of somatic alterations (SAS). Ann Oncol 2017;28 10.1093/annonc/mdx376.006 - DOI

Publication types